

North Central Cancer Treatment Group

N057K: Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ)
Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed
Glioblastoma

Status Change – March 3, 2009

NOTICE OF STATUS CHANGE

The Phase I portion of this study will be reopening to Mayo (Rochester and Jacksonville) at dose level 2 (70 mg/week everolimus, 6000cGy RT, 75 mg/m²/day TMZ) for 6 patients effective March 3, 2009.

Please retain this notice with the protocol.